The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-05), Cue Biopharma's 9-Day RSI is 52.34.
The industry rank for Cue Biopharma's 9-Day RSI or its related term are showing as below:
CUE's 9-Day RSI is ranked better than 53.46% of 1418
companies
in the Biotechnology industry
Industry Median: 53.73
vs CUE: 52.34
Cue Biopharma (NAS:CUE) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Cue Biopharma 9-Day RSI Related Terms
CUE vs ALPS, AARD, KLRS: 9-Day RSI Comparison
For the Biotechnology subindustry, Cue Biopharma's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cue Biopharma 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cue Biopharma's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Cue Biopharma's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cue Biopharma (CUE) has a 9-Day RSI of 52.34 as of Jul. 05, 2026. According to the industry distribution chart, Cue Biopharma ranks #660 out of 1418 companies in the Biotechnology industry, placing it in the top 46.5%.
Is Cue Biopharma's 9-Day RSI too high?
Cue Biopharma's current 9-Day RSI is 52.34. The Biotechnology industry median 9-Day RSI is 53.73. Cue Biopharma's value of 52.34 is 2.6% below this industry median. Based on the distribution chart, Cue Biopharma ranks #660 out of 1418 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cue Biopharma has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cue Biopharma's 9-Day RSI compare to ALPS and AARD?
According to the Biotechnology industry distribution chart, Cue Biopharma ranks #660 out of 1418 companies for 9-Day RSI. This puts Cue Biopharma in the upper half of its industry. The industry median 9-Day RSI is 53.73. Cue Biopharma's value of 52.34 is 2.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 53.73, based on 1,418 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cue Biopharma's current 9-Day RSI of 52.34 is 2.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 53.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cue Biopharma's current 9-Day RSI is 52.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cue Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cue Biopharma (CUE) is currently considered Possible Value Trap. The stock's GF Value™ is $62.39, compared to a current price of $28.33 — trading 54.6% below its estimated fair value. The current 9-Day RSI is 52.34 and 2.6% below the Biotechnology industry median of 53.73. Cue Biopharma's overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Cue Biopharma (CUE), the current 9-Day RSI is 52.34 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cue Biopharma (CUE) Overvalued in 2026?
Based on GuruFocus' analysis, Cue Biopharma stock appears to be undervalued.
The current stock price of $28.33 is trading 54.6% below its estimated GF Value™ of $62.39.
GuruFocus considers Cue Biopharma to be Possible Value Trap.
Key valuation signals for CUE:
9-Day RSI: 52.34
GF Value™: $62.39 vs. price of $28.33 (54.6% below fair value)
Industry Position: 2.6% below the Biotechnology median (#660 of 1418)
No single metric tells the full story. See the CUE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
59GF Score
Get the complete analysis for CUE
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CUE has been successfully added to your 